 |
인쇄하기
취소
|
Cumulative sales of Kanarb surpass 10 billion
Boryung Pharmaceutical said its new hypertensive drug Kanarb (fimasartan) generated 10 billion won in sales since its launching last March of last year.
Kanarb’s sales will get a momentum if it is to be successfully landed in general hospitals, Boryung officials said.
Kanarb, angiotensin II receptor (AT1) antagonist, mark the 18th new medicine developed by a local drug manufacturer. The d...
Kanarb’s sales will get a momentum if it is to be successfully landed in general hospitals, Boryung officials said.
Kanarb, angiotensin II receptor (AT1) antagonist, mark the 18th new medicine developed by a local drug manufacturer. The d...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.